SonoThera raised $125 million to advance its ultrasound-based, microbubble-mediated non-viral gene delivery platform into clinical development. The financing is intended to propel lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease. The company’s strategy focuses on using ultrasound to activate microbubbles after administration of nucleic acids, aiming to improve delivery safety and broaden applicability beyond rare diseases, while addressing limitations associated with viral vectors and conventional lipid nanoparticles. For the gene therapy sector, the round reflects sustained funding interest in delivery innovations designed to overcome durability, dosing, and manufacturing bottlenecks.